Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Valgimigli, M.
Right arrow Articles by Abbate, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Valgimigli, M.
Right arrow Articles by Abbate, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after myocardial infarction

Marco Valgimigli1,*, Giuseppe G.L. Biondi-Zoccai2, Patrizia Malagutti1, Antonio Maria Leone3 and Antonio Abbate4

1 Institute of Cardiology, University of Ferrara and Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS, GS, Arcispedale S. Anna, Corso Giovecca 203, 44100 Ferrara, Italy
2 Interventional Cardiology, Division of Cardiology, University of Turin, Turin, Italy
3 Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy
4 VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA

* Corresponding author. Tel: +39 0532 202143; fax: +39 0532 241885. E-mail address: vlgmrc{at}unife.it

Nine randomized controlled studies have so far evaluated the safety and efficacy profile Granulocyte-colony stimulating factor (G-CSF) in the setting of the acute/subacute phase of myocardial infarction (MI) in humans on a total of 409 patients. The drug, administered at various regimen, ranging from 2.5 to 10 mg/kg for a minimum of 4 to a maximum of 6 days, has been well tolerated. In one single prematurely stopped study (MAGIC), safety concerns were raised by an unexpected high restenosis rate in stented vessel. This was not confirmed in all subsequent studies. A clear improvement in the treated vs. control group at follow-up in left ventricular (LV) function/remodelling indexes has been reported in two studies (FIRST-LINE and RIGENERA). In a third investigation, LV ejection fraction improved in the treated but not in the control group with respect to baseline, but no significant difference emerged between G-CAF and placebo group at follow-up (Takano et al.). In all other six studies, no clear effect of treatment was noted. Future properly powered randomized controlled studies ideally targeting patients with large anterior MI with poor response to early reperfusion are warranted to further clarify the role of G-CSF in this setting.

Key Words: Granulocyte-colony stimulating factor • Myocardial infarction • Bone-marrow • CD34 antigen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Heart JHome page
A. M. Leone, M. Valgimigli, M. B. Giannico, V. Zaccone, M. Perfetti, D. D'Amario, A. G. Rebuzzi, and F. Crea
From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells
Eur. Heart J., April 2, 2009; 30(8): 890 - 899.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.